It looks like Eli Lilly’s oral selective estrogen receptor degrader (SERD) imlunestrant may need some extra help to reach a ...

AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...

The U.S. Preventive Services Task Force pitched an update to its guidelines for cervical cancer screening, endorsing HPV ...

A Maryland jury has convicted both former CytoDyn CEO Nader Pourhassan, Ph.D., and ex-Amarex CEO Kazem Kazempour on several ...

Hepion Pharmaceuticals and Pharma Two B have terminated a reverse merger agreement that was expected to close by the end of ...

A phase 3 prostate cancer trial of Candel’s oncolytic virus has met its primary endpoint, sending the stock up more than 200% ...

Danish pharma company Bavarian Nordic is shutting down its U.S.-based R&D site in San Diego and laying off all 48 employees ...

Q32 Bio still sees potential for its anti-IL-7R antibody as an alopecia treatment despite failing a phase 2 eczema study—but ...

Capstan Medical has reeled in $110 million to continue its mission of bringing robotic surgery to a previously untouched ...

Cellectar Biosciences is laying off 60% of its employees and halting work on its sole clinical-stage radiotherapy after the ...

Two Boston-area biotechs are shedding staff and merging together to form a new genetic medicines company. | Chroma Medicines ...

Spruce Biosciences has trimmed the only drug from its pipeline in the wake of a second phase 2 failure this year, leaving the ...